NasdaqCM - Nasdaq Real Time Price • USD
Agenus Inc. (AGEN)
As of 10:29 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
156,314.00
156,314.00
98,024.00
295,665.00
88,170.00
Cost of Revenue
237,680.00
237,680.00
197,259.00
182,078.00
144,966.00
Gross Profit
-81,366.00
-81,366.00
-99,235.00
113,587.00
-56,796.00
Operating Expense
78,739.00
78,739.00
81,007.00
76,359.00
59,218.00
Operating Income
-160,105.00
-160,105.00
-180,242.00
37,228.00
-116,014.00
Net Non Operating Interest Income Expense
-97,925.00
-97,925.00
-61,863.00
-65,719.00
-61,078.00
Other Income Expense
593.00
593.00
11,449.00
-233.00
-5,799.00
Pretax Income
-257,437.00
-257,437.00
-230,656.00
-28,724.00
-182,891.00
Net Income Common Stockholders
-245,974.00
-245,974.00
-220,286.00
-24,137.00
-181,123.00
Diluted NI Available to Com Stockholders
-245,974.00
-245,974.00
-220,286.00
-24,137.00
-181,123.00
Basic EPS
-0.69
--
-0.78
-0.11
-1.05
Diluted EPS
-0.69
--
-0.78
-0.11
-1.05
Basic Average Shares
357,889.00
--
281,743.00
228,919.00
172,504.00
Diluted Average Shares
357,889.00
--
281,743.00
228,919.00
172,504.00
Total Operating Income as Reported
-159,549.00
-159,549.00
-179,427.00
25,747.00
-117,235.00
Total Expenses
316,419.00
316,419.00
278,266.00
258,437.00
204,184.00
Net Income from Continuing & Discontinued Operation
-245,761.00
-245,761.00
-220,074.00
-23,926.00
-180,914.00
Normalized Income
-246,317.00
-246,317.00
-218,952.00
-18,642.00
-176,973.00
Interest Expense
97,925.00
97,925.00
61,863.00
65,719.00
61,078.00
Net Interest Income
-97,925.00
-97,925.00
-61,863.00
-65,719.00
-61,078.00
EBIT
-159,512.00
-159,512.00
-168,793.00
36,995.00
-121,813.00
EBITDA
-145,924.00
-145,924.00
-161,847.00
43,783.00
-114,634.00
Reconciled Cost of Revenue
237,680.00
237,680.00
197,259.00
182,078.00
144,966.00
Reconciled Depreciation
13,588.00
13,588.00
6,946.00
6,788.00
7,179.00
Net Income from Continuing Operation Net Minority Interest
-245,761.00
-245,761.00
-220,074.00
-23,926.00
-180,914.00
Total Unusual Items Excluding Goodwill
556.00
556.00
-1,122.00
-5,284.00
-3,941.00
Total Unusual Items
556.00
556.00
-1,122.00
-5,284.00
-3,941.00
Normalized EBITDA
-146,480.00
-146,480.00
-160,725.00
49,067.00
-110,693.00
12/31/2020 - 2/8/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INKT MiNK Therapeutics, Inc.
0.9273
+3.72%
GERN Geron Corporation
3.8050
+2.01%
ADAP Adaptimmune Therapeutics plc
1.0700
+5.94%
BLUE bluebird bio, Inc.
1.0200
+6.96%
CHRS Coherus BioSciences, Inc.
2.1850
+0.23%
IOVA Iovance Biotherapeutics, Inc.
11.62
+2.61%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1616
+3.99%
VNDA Vanda Pharmaceuticals Inc.
4.8501
+1.04%
TGTX TG Therapeutics, Inc.
14.29
+1.35%
KPTI Karyopharm Therapeutics Inc.
1.1499
+1.76%